Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on October 20, 2008

Circulation. 2008
Published online before print October 20, 2008, doi: 10.1161/CIRCULATIONAHA.108.791533
A more recent version of this article appeared on November 4, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
118/19/1970    most recent
CIRCULATIONAHA.108.791533v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by West, M. B.
Right arrow Articles by Bhatnagar, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by West, M. B.
Right arrow Articles by Bhatnagar, A.
Related Collections
Right arrow Acute myocardial infarction
Right arrowRelated Article

Submitted on October 10, 2007
Accepted on July 7, 2008

Cardiac Myocyte–Specific Expression of Inducible Nitric Oxide Synthase Protects Against Ischemia/Reperfusion Injury by Preventing Mitochondrial Permeability Transition

Matthew B. West PhD, Gregg Rokosh PhD, Detlef Obal MD, Murugesan Velayutham PhD, Yu-Ting Xuan PhD, Bradford G. Hill PhD, Rachel J. Keith MS, Jürgen Schrader MD, Yiru Guo MD, Daniel J. Conklin PhD, Sumanth D. Prabhu MD, Jay L. Zweier MD, Roberto Bolli MD, and Aruni Bhatnagar PhD*

From the Institute of Molecular Cardiology (M.B.W., G.R., Y.-T.X., B.G.H., R.J.K., Y.G., D.J.C., S.D.P., R.B., A.B.), Department of Biochemistry and Molecular Biology (M.B.W., B.G.H.), VA Medical Center (S.D.P.), and Department of Anesthesiology and Perioperative Medicine (D.O.), University of Louisville, Louisville, Ky; Department of Cardiovascular Physiology (J.S.) and Department of Anesthesiology (D.O.), University of Düsseldorf, Düsseldorf, Germany; and Center for Biomedical EPR Spectroscopy and Imaging, Davis Heart and Lung Research Institute, and Division of Cardiovascular Medicine, Department of Internal Medicine, Ohio State University College of Medicine, Columbus (M.V., J.L.Z.).

* To whom correspondence should be addressed. E-mail: aruni{at}louisville.edu.

Background—Inducible nitric oxide synthase (iNOS) is an obligatory mediator of the late phase of ischemic preconditioning, but the mechanisms of its cardioprotective actions are unknown. In addition, it remains unclear whether sustained elevation of iNOS in myocytes provides chronic protection against ischemia/reperfusion injury.

Methods and Results—Constitutive overexpression of iNOS in transgenic mice ({alpha}-myosin heavy chain promoter) did not induce contractile dysfunction and did not affect mitochondrial respiration or biogenesis, but it profoundly decreased infarct size in mice subjected to 30 minutes of coronary occlusion and 24 hours of reperfusion. In comparison with wild-type hearts, isolated iNOS-transgenic hearts subjected to ischemia for 30 minutes followed by 40 minutes of reperfusion displayed better contractile recovery, smaller infarct size, and less mitochondrial entrapment of 2-deoxy-[3H]-glucose. Reperfusion-induced loss of NAD+ and mitochondrial release of cytochrome c were attenuated in iNOS-transgenic hearts, indicating reduced mitochondrial permeability transition. The NO donor NOC-22 prevented permeability transition in isolated mitochondria, and mitochondrial permeability transition–induced NAD+ loss was decreased in wild-type but not iNOS-null mice treated with the NO donor diethylene triamine/NO 24 hours before ischemia and reperfusion ex vivo. iNOS-mediated cardioprotection was not abolished by atractyloside. Reperfusion-induced production of oxygen-derived free radicals (measured by electron paramagnetic resonance spectroscopy) was attenuated in iNOS-transgenic hearts and was increased in wild-type hearts treated with the mitochondrial permeability transition inhibitor cyclosporin A.

Conclusions—Cardiomyocyte-restricted expression of iNOS provides sustained cardioprotection. This cardioprotection is associated with a decrease in reperfusion-induced oxygen radicals and inhibition of mitochondrial swelling and permeability transition.


Key words: infarction • ischemia • nitric oxide • nitric oxide synthase


Related Article:

Clinical Summaries
Circulation 2008 118: 1911-1912. [Extract] [Full Text]



This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
I. Moench, H. Prentice, Z. Rickaway, and H. Weissbach
Sulindac confers high level ischemic protection to the heart through late preconditioning mechanisms
PNAS, November 17, 2009; 106(46): 19611 - 19616.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Boengler, R. Schulz, and G. Heusch
Loss of cardioprotection with ageing
Cardiovasc Res, July 15, 2009; 83(2): 247 - 261.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. Heusch, K. Boengler, and R. Schulz
Cardioprotection: Nitric Oxide, Protein Kinases, and Mitochondria
Circulation, November 4, 2008; 118(19): 1915 - 1919.
[Full Text] [PDF]